VCYT (Veracyte) FFO


VCYT Veracyte Inc VCYT
75 GF Score
Price $60.05
GF Value $38.10
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Veracyte FFO?

FFO (Funds from operations) only applies to REITs.

VCYT
75GF Score
Veracyte Inc VCYT
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Veracyte (VCYT) Overvalued in 2026?

Based on GuruFocus' analysis, Veracyte stock appears to be overvalued. The current stock price of $60.05 is trading 57.6% above its estimated GF Value™ of $38.10. GuruFocus considers Veracyte to be Significantly Overvalued.

Key valuation signals for VCYT:

  • FFO:
  • GF Value™: $38.10 vs. price of $60.05 (57.6% above fair value)
  • GF Score™: 75/100 with 7 warning signs

No single metric tells the full story. See the VCYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Veracyte Business Description

Other Exchanges 12V:Germany
Address 6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
75GF Score

Get the complete analysis for VCYT

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$60.05
Price
$38.10
GF Value